Zerbor
- Denali Therapeutics (NASDAQ:DNLI) closed down 11% Friday as investors seemed concerned about the biopharma's projected rise in operating expenses for 2025.
- In its Q4 and full-year 2024 financial results released after Thursday's closing bell, the company said it anticipated a 10%-15% increase